{"entity":{"type":"insider","cik":"0001678984","url":"/insider/0001678984","json_url":"/insider/0001678984.json","name":"Schilke Tobin","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":20,"n_filings":17,"first":"2017-01-30","last":"2026-03-04","span_basis":"filed_date"},"name_variants":[{"name":"Schilke Tobin","source":"filing","n_filings":17,"first_seen":"2017-01-30","last_seen":"2026-03-04"}],"transactions":[{"id":6187887,"accession":"0001628280-26-014772","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-26-014772","line_url":"/filing/0001628280-26-014772#line-1","is_derivative":false,"issuer_cik":"0001658247","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001658247","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6713.0,"shares_display":"6,713","price_per_share":39.67,"price_display":"39.67","price_state":"stated","total_value":266304.71,"total_display":"266,304.71","total_whole":"266,305","shares_owned_after":78121.0,"shares_owned_after_display":"78,121","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-03","filed_date":"2026-03-04","scope":"insider"},{"id":2424985,"accession":"0001479290-24-000066","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001479290-24-000066","line_url":"/filing/0001479290-24-000066#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9361.0,"shares_display":"9,361","price_per_share":5.0426,"price_display":"5.04","price_state":"stated","total_value":47203.7786,"total_display":"47,203.78","total_whole":"47,204","shares_owned_after":192666.0,"shares_owned_after_display":"192,666","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-18","filed_date":"2024-03-19","scope":"insider"},{"id":8233897,"accession":"0001479290-23-000083","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001479290-23-000083","line_url":"/filing/0001479290-23-000083#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1701.0,"shares_display":"1,701","price_per_share":25.04,"price_display":"25.04","price_state":"stated","total_value":42593.04,"total_display":"42,593.04","total_whole":"42,593","shares_owned_after":79896.0,"shares_owned_after_display":"79,896","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-07-03","filed_date":"2023-07-05","scope":"insider"},{"id":7877383,"accession":"0001479290-23-000077","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001479290-23-000077","line_url":"/filing/0001479290-23-000077#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":31.0,"price_display":"31.00","price_state":"stated","total_value":15500.0,"total_display":"15,500.00","total_whole":"15,500","shares_owned_after":80828.0,"shares_owned_after_display":"80,828","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-02","filed_date":"2023-06-05","scope":"insider"},{"id":7877379,"accession":"0001479290-23-000077","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-23-000077","line_url":"/filing/0001479290-23-000077#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2701.0,"shares_display":"2,701","price_per_share":30.57,"price_display":"30.57","price_state":"stated","total_value":82569.57,"total_display":"82,569.57","total_whole":"82,570","shares_owned_after":81328.0,"shares_owned_after_display":"81,328","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-01","filed_date":"2023-06-05","scope":"insider"},{"id":7877374,"accession":"0001479290-23-000075","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001479290-23-000075","line_url":"/filing/0001479290-23-000075#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21401.0,"shares_display":"21,401","price_per_share":34.5469,"price_display":"34.55","price_state":"stated","total_value":739338.2069,"total_display":"739,338.21","total_whole":"739,338","shares_owned_after":84029.0,"shares_owned_after_display":"84,029","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-15","filed_date":"2023-05-16","scope":"insider"},{"id":8496540,"accession":"0001479290-23-000056","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-23-000056","line_url":"/filing/0001479290-23-000056#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3201.0,"shares_display":"3,201","price_per_share":31.7,"price_display":"31.70","price_state":"stated","total_value":101471.7,"total_display":"101,471.70","total_whole":"101,472","shares_owned_after":63081.0,"shares_owned_after_display":"63,081","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-01","filed_date":"2023-05-02","scope":"insider"},{"id":8367077,"accession":"0001479290-23-000053","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-23-000053","line_url":"/filing/0001479290-23-000053#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3201.0,"shares_display":"3,201","price_per_share":32.15,"price_display":"32.15","price_state":"stated","total_value":102912.15,"total_display":"102,912.15","total_whole":"102,912","shares_owned_after":66282.0,"shares_owned_after_display":"66,282","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-03","filed_date":"2023-04-04","scope":"insider"},{"id":7877366,"accession":"0001479290-23-000036","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001479290-23-000036","line_url":"/filing/0001479290-23-000036#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18517.0,"shares_display":"18,517","price_per_share":31.5863,"price_display":"31.59","price_state":"stated","total_value":584883.5171,"total_display":"584,883.52","total_whole":"584,884","shares_owned_after":73222.0,"shares_owned_after_display":"73,222","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-09","filed_date":"2023-03-09","scope":"insider"},{"id":8367071,"accession":"0001479290-23-000031","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-23-000031","line_url":"/filing/0001479290-23-000031#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3201.0,"shares_display":"3,201","price_per_share":33.5,"price_display":"33.50","price_state":"stated","total_value":107233.5,"total_display":"107,233.50","total_whole":"107,234","shares_owned_after":49390.0,"shares_owned_after_display":"49,390","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-02","scope":"insider"},{"id":8329193,"accession":"0001479290-23-000015","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-23-000015","line_url":"/filing/0001479290-23-000015#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3201.0,"shares_display":"3,201","price_per_share":34.6,"price_display":"34.60","price_state":"stated","total_value":110754.6,"total_display":"110,754.60","total_whole":"110,755","shares_owned_after":54676.0,"shares_owned_after_display":"54,676","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-01","filed_date":"2023-02-02","scope":"insider"},{"id":8482220,"accession":"0001479290-23-000012","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-23-000012","line_url":"/filing/0001479290-23-000012#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":31.0,"price_display":"31.00","price_state":"stated","total_value":31000.0,"total_display":"31,000.00","total_whole":"31,000","shares_owned_after":57877.0,"shares_owned_after_display":"57,877","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-20","filed_date":"2023-01-23","scope":"insider"},{"id":8367067,"accession":"0001479290-23-000007","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001479290-23-000007","line_url":"/filing/0001479290-23-000007","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3701.0,"shares_display":"3,701","price_per_share":27.161577951904892,"price_display":"27.16","price_state":"stated","total_value":100525.0,"total_display":"100,525.00","total_whole":"100,525","shares_owned_after":60877.0,"shares_owned_after_display":"60,877","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-09","filed_date":"2023-01-10","scope":"insider","n_lines":3},{"id":6228195,"accession":"0001140361-18-030425","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-18-030425","line_url":"/filing/0001140361-18-030425#line-2","is_derivative":false,"issuer_cik":"0001301501","issuer_name":"Achaogen Inc","issuer_ticker":"AKAO","issuer_name_source":null,"issuer_url":"/issuer/0001301501","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":298.0,"shares_display":"298","price_per_share":9.59,"price_display":"9.59","price_state":"stated","total_value":2857.82,"total_display":"2,857.82","total_whole":"2,858","shares_owned_after":47748.0,"shares_owned_after_display":"47,748","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-26","filed_date":"2018-06-28","scope":"insider"},{"id":6489827,"accession":"0001140361-18-028440","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-18-028440","line_url":"/filing/0001140361-18-028440#line-1","is_derivative":false,"issuer_cik":"0001301501","issuer_name":"Achaogen Inc","issuer_ticker":"AKAO","issuer_name_source":null,"issuer_url":"/issuer/0001301501","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2087.0,"shares_display":"2,087","price_per_share":11.95,"price_display":"11.95","price_state":"stated","total_value":24939.65,"total_display":"24,939.65","total_whole":"24,940","shares_owned_after":47186.0,"shares_owned_after_display":"47,186","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-11","filed_date":"2018-06-13","scope":"insider"},{"id":6612637,"accession":"0001140361-18-009970","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-18-009970","line_url":"/filing/0001140361-18-009970#line-1","is_derivative":false,"issuer_cik":"0001301501","issuer_name":"Achaogen Inc","issuer_ticker":"AKAO","issuer_name_source":null,"issuer_url":"/issuer/0001301501","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1108.0,"shares_display":"1,108","price_per_share":10.67,"price_display":"10.67","price_state":"stated","total_value":11822.36,"total_display":"11,822.36","total_whole":"11,822","shares_owned_after":40185.0,"shares_owned_after_display":"40,185","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-02-21","filed_date":"2018-02-23","scope":"insider"},{"id":4412587,"accession":"0001140361-17-025045","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-17-025045","line_url":"/filing/0001140361-17-025045#line-1","is_derivative":false,"issuer_cik":"0001301501","issuer_name":"Achaogen Inc","issuer_ticker":"AKAO","issuer_name_source":null,"issuer_url":"/issuer/0001301501","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2066.0,"shares_display":"2,066","price_per_share":21.53,"price_display":"21.53","price_state":"stated","total_value":44480.98,"total_display":"44,480.98","total_whole":"44,481","shares_owned_after":40119.0,"shares_owned_after_display":"40,119","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-06-12","filed_date":"2017-06-14","scope":"insider"},{"id":4786973,"accession":"0001140361-17-003552","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-17-003552","line_url":"/filing/0001140361-17-003552#line-1","is_derivative":false,"issuer_cik":"0001301501","issuer_name":"Achaogen Inc","issuer_ticker":"AKAO","issuer_name_source":null,"issuer_url":"/issuer/0001301501","owner_cik":"0001678984","owner_name":"Schilke Tobin","owner_display_name":"Schilke Tobin","owner_url":"/insider/0001678984","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":955.0,"shares_display":"955","price_per_share":16.78,"price_display":"16.78","price_state":"stated","total_value":16024.9,"total_display":"16,024.90","total_whole":"16,025","shares_owned_after":26045.0,"shares_owned_after_display":"26,045","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-26","filed_date":"2017-01-30","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":20,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":20,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":20},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001658247","name":"Crinetics Pharmaceuticals, Inc.","url":"/issuer/0001658247","role":"Officer (Chief Financial Officer)","n_filings":1,"first_seen":"2026-03-04","last_seen":"2026-03-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001479290","name":"Revance Therapeutics, Inc.","url":"/issuer/0001479290","role":"Officer (CFO)","n_filings":11,"first_seen":"2023-01-10","last_seen":"2024-03-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001301501","name":"Achaogen Inc","url":"/issuer/0001301501","role":"Officer (Chief Financial Officer)","n_filings":5,"first_seen":"2017-01-30","last_seen":"2018-06-28"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001678984","retrieved_at":"2026-08-27T03:26:46+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}